Login / Signup

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.

Julie DubourgSandrine Perrimond-DauchyMathieu FelicesSébastien BolzePascal VoiriotPascale Fouqueray
Published in: European journal of clinical pharmacology (2020)
NCT02924337/ October 5, 2016.
Keyphrases
  • drug induced
  • type diabetes
  • cardiovascular disease
  • metabolic syndrome
  • skeletal muscle